相关实验视频

Updated: May 29, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

在接受皮肤冠状动脉干预的急性冠状动脉综合征患者的临床结果上,炎症和出血风险

Yixuan Duan^1,2, Miaohan Qiu¹, Kun Na¹

¹Department of Cardiology, State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China.

Thrombosis and haemostasis

|February 4, 2025

概括

通过高灵敏度C反应蛋白 (hsCRP) 测量系统性炎症,在经皮冠状动脉干预 (PCI) 后的急性冠状动脉综合征 (ACS) 患者中增加缺血事件和死亡风险. 这种关联不管出血风险状况如何,都适用,并不能预测出血事件.

科学领域:

心脏病学心脏病学
生物标志物生物标志物
干预心脏病学干预心脏病学

背景情况:

系统性炎症在急性冠状动脉综合征 (ACS) 病理生理学中起作用.
高敏感性C反应蛋白 (hsCRP) 是系统性炎症的标志物.
在接受皮肤冠状动脉干预 (PCI) 的 ACS 患者中,出血风险分层是至关重要的.

研究的目的:

评估系统性炎症负担 (hsCRP) 对PCI后ACS患者的长期预后的影响.
为了评估这种影响,按高出血风险 (HBR) 状态分层.
确定hsCRP水平与缺血和出血事件之间的关系.

主要方法:

分析了15013名连续接受PCI的ACS患者 (2016年3月至2022年3月).
系统性炎症定义为hsCRP>2 mg/L;根据学术研究联盟 (ARC) -HBR标准定义的高出血风险.
主要结局:12个月:缺血性事件 (心脏死亡,心肌梗塞,中风). 二次结果:全因死亡和出血事件 (BARC类型2,3,5).

主要成果:

升高的hsCRP与HBR和非HBR亚组中缺血事件的风险更高有关.
在非HBR患者中观察到hsCRP和缺血事件/全因死亡之间的反向J形关系.
升高的hsCRP没有与出血事件的风险增加有关,无论HBR状态如何.

结论:

高hsCRP水平表明,在PCI后的ACS患者中,缺血事件和全因死亡风险增加,独立于出血风险.
hsCRP是接受PCI的ACS患者缺血并发症的有价值的预后标志物.
在这种患者群体中,hsCRP水平似乎无法预测出血风险.

更多相关视频

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...